MedImmune, LLC (MedImmune)

Oncology Corporate Profile

HQ Location

One MedImmune Way
Gaithersburg, MD 20878

Company Description

MedImmune is the worldwide biologics research and development arm of AstraZeneca. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca's three global R&D centres


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tremelimumabanti CTLA-4 monoclonal antibodyMesotheliomaIII
MEDI-4736monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)IIIAstrazeneca
moxetumomab pasudotox / CAT-8015anti-CD22 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)III
MEDI-573anti-IGF monoclonal antibody1st line metastatic Breast cancer (HER2-)IIAstrazeneca
MEDI-575anti-PDGFR monoclonal antibody2nd line metastatic Glioblastoma Multiforme (GBM)IIAstrazeneca
MEDI-551anti-CD19 monoclonal antibodyChronic Lymphocytic Leukemia (CLL)II
MEDI-551anti-CD19 monoclonal antibodyDiffuse large B-cell Lymphoma (DLBCL)II
MEDI-575anti-PDGFR monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)IIAstrazeneca
moxetumomab pasudotox / CAT-8015anti-CD22 monoclonal antibodyChronic Lymphocytic Leukemia (CLL)I
MEDI-573 (+ sorafenib)anti-IGF monoclonal antibodyHepatocellular carcinoma (HCC)IAstrazeneca
MEDI-4736 (+ gefitinib)monoclonal antibodyNon Small Cell Lung Cancer (NSCLC)IAstrazeneca
MEDI-551anti-CD19 monoclonal antibodyNon-Hodgkin's Lymphoma (NHL)IAstrazeneca
MEDI-6469monoclonal antibodyVarious cancer typesI
AMP-514monoclonal antibodyVarious cancer typesI
MEDI-0639human monoclonal antibody to delta-like ligand-4 (Dll4)Various cancer typesI
MEDI-4736 (+ mocetinostat)monoclonal antibodyVarious cancer typesIMirati
MEDI3617anti-Ang2 monoclonal antibodyVarious cancer typesI
MEDI-573anti-IGF monoclonal antibodyVarious cancer typesIAstrazeneca
MEDI-565 (MT111)CEA BiTEĀ® antibodyVarious cancer typesIMicromet
MEDI-551 (+ rituximab)anti-CD19 monoclonal antibodyVarious cancer typesI
Medi0680anti-PD-1 MAb inhibitorVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display